20 articles
A Phase II pilot trial tests whether adding carfilzomib to plasma exchange and IVIG can safely reverse antibody-mediated rejection after lung transplantation.
A rigorous 2025 review finds no approved AMR therapy and reassesses all current evidence, spotlighting CD38 antibodies and complement inhibition.
A major review outlines how targeted hematologic therapies are transforming outcomes in MGRS, a rare but serious cause of kidney injury.
Breakthrough treatments targeting specific immune pathways show promise for reducing steroid dependence in EGPA patients.
Authors reply to commentary on a landmark NEJM trial combining ianalumab and eltrombopag for immune thrombocytopenia.
A randomized phase 2 trial finds CM313 achieves 83% response rate vs 20% placebo in treatment-resistant immune thrombocytopenia.
Researchers develop standardized lung washing procedure that rapidly improves breathing and quality of life in patients with rare disease.
Scientists identify key mechanism that determines why some immune thrombocytopenia patients maintain remission after stopping treatment.
A completed Phase 3 trial tests placental MSC secretome injections against placebo in 60 GvHD patients at an Iranian hospital.
Researchers modified red blood cells to teach the immune system tolerance, potentially ending need for harsh immunosuppressive drugs.
Engineered immune cells offer new hope for treating kidney diseases that resist standard therapies, potentially improving long-term health outcomes.
A 2025 review from Johns Hopkins outlines how to accurately diagnose complement-mediated TMA using functional assays and systematic testing.
A major review in Nature Medicine explores how CAR cell therapies may achieve deep immune 'reset' in autoimmune diseases by depleting pathogenic B cells.
Small study tests whether tocilizumab can achieve faster, deeper remission in newly diagnosed rheumatoid arthritis patients.
A Phase 2 trial testing rituximab, infliximab, and tocilizumab for hard-to-treat non-ANCA vasculitis was terminated before completion.
A completed Phase 3 trial evaluated whether the anti-TNF biologic infliximab safely and effectively treats plaque psoriasis.
Revolutionary cancer treatment successfully treats treatment-resistant autoimmune disease, offering hope for severe cases.
A phase 1/2 trial finds low-dose oral NMN safely raises platelet counts in steroid-refractory ITP via a novel immunometabolic mechanism.
A Phase 4 trial compares two antiretroviral strategies in treatment-naive HIV patients with dangerously low CD4 counts below 100.
New cell-based treatments including CAR-T therapy could transform outcomes for systemic sclerosis patients.
